Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Pembrolizumab v kombinaci s chemoterapií pro léčbu křehkých pacientů s Hodgkinovým lymfomem, kteří nejsou způsobilí pro standardní léčbu

9. listopadu 2026 aktualizováno: City of Hope Medical Center

Fáze 2 studie Pembrolizumabu s chemoterapií u křehkých pacientů s nově diagnostikovaným klasickým Hodgkinovým lymfomem

This phase II trial tests how well pembrolizumab in addition to chemotherapy (gemcitabine, brentuximab vedotin, and dacarbazine) works in treating frail patients with newly diagnosed Hodgkin lymphoma who aren't candidates for standard anthracycline-based treatment. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. Dacarbazine is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill cancer cells and slow down or stop cancer growth. Pembrolizumab in combination chemotherapy may be a safe and effective alternative treatment option for frail patients with Hodgkin lymphoma who can't receive standard anthracycline-based treatment.

Přehled studie

Detailní popis

PRIMARY OBJECTIVE:

I. Estimate the best complete metabolic response (CMR) rate for frail patients with classical Hodgkin lymphoma (cHL) who receive pembrolizumab and gemcitabine (P-G).

SECONDARY OBJECTIVES:

I. Estimate CMR rate, overall response rate (ORR), progression-free-survival (PFS), duration of response (DOR), and overall response (OS) among patients who receive P-G (± pembrolizumab maintenance).

II. Estimate CMR, overall response, PFS, DOR, and OS among patients who receive pembrolizumab, brentuximab vedotin, and dacarbazine (P-BV-D).

III. Evaluate the toxicity of P-G, pembrolizumab maintenance, and P-BV-D.

EXPLORATORY OBJECTIVES:

I. Explore association between geriatric assessment measures (Cancer and Aging Research Group [CARG] geriatric assessment) and toxicity and efficacy in the elderly patients enrolled on this trial.

II. Assess functional trajectory determined by short physical performance battery (SPPB) change score in the elderly patients enrolled on this trial.

III. Explore the association between clinical outcomes and pathological tumor characteristics.

OUTLINE:

CYCLES 1-8: Patients receive pembrolizumab intravenously (IV) over 30 minutes and gemcitabine IV on day 1 of each cycle. Cycles repeat every 21 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity. Patients without progressive disease during or at the completion of 8 cycles of P-G proceed to maintenance therapy. Patients with progressive disease during or at the completion of 8 cycles of P-G proceed to salvage therapy.

MAINTENANCE THERAPY: Patients receive pembrolizumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 42 days for up to 4 cycles (cycles 9-12) in the absence of disease progression or unacceptable toxicity.

SALVAGE THERAPY: Patients receive pembrolizumab IV over 30 minutes, brentuximab vedotin IV over 30 minutes, and dacarbazine IV on day 1 of each cycle. Cycles repeat every 21 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

Patients undergo positron emission tomography (PET)/computed tomography (CT) and collection of blood samples throughout the trial and may undergo echocardiography (ECHO) at screening if indicated.

After completion of study treatment, patients are followed up at 30 days and at 12, 18 (salvage patients), and 24 months.

Typ studie

Intervenční

Zápis (Odhadovaný)

23

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • California
      • Duarte, California, Spojené státy, 91010
        • Nábor
        • City of Hope Medical Center
        • Kontakt:
          • Matthew Mei
          • Telefonní číslo: 626-218-2405
          • E-mail: mamei@coh.org
        • Vrchní vyšetřovatel:
          • Matthew Mei

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Meets at least one of the following criteria indicating unsuitability for conventional anthracycline-based frontline chemotherapy, as determined by the investigator:

    • Age ≥ 75 years
    • Eastern Cooperative Oncology Group (ECOG) 2-4
    • Left ventricular ejection fraction (LVEF) < 50%
    • Creatinine clearance < 60 mL/min, using Cockcroft-Gault formula or equivalent
    • Pulmonary function impairment: forced expiratory volume in 1 second (FEV1) < 50% and/or diffusion capacity of the lung for carbon monoxide (DLCO) < 50%
  • ECOG ≤ 2

  • Age ≥ 18 years

  • Histologically confirmed new diagnosis of classical Hodgkin lymphoma (excluding nodular lymphocyte predominant Hodgkin lymphoma) according to the World Health Organization (WHO) classification, with hematopathology review at the participating institution

  • No prior systemic treatment for classical Hodgkin lymphoma with the following exceptions: a course of systemic corticosteroids for palliation of symptoms related to the classical Hodgkin lymphoma is allowed but must be stopped by cycle 1 day 1 (C1D1) as well as prior treatment with P-G as part of this clinical trial for patients will receive P-BV-D

  • Measurable disease (at least one non-bone fludeoxyglucose F-18 [FDG]-avid lesion ≥ 1.5 cm in long axis)

  • Absolute neutrophil count (ANC) ≥ 1,000/mm^3

    • NOTE: Growth factor is not permitted within 7 days of ANC assessment unless cytopenia is secondary to disease involvement
  • Platelets ≥ 50,000/mm^3

    • NOTE: Platelet transfusions are not permitted within 7 days of platelet assessment unless cytopenia is secondary to disease involvement
  • Total bilirubin ≤ 2 × upper limit of normal (ULN) or direct bilirubin ≤ 2 × ULN for patients with Gilbert's disease

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN

  • AST and ALT ≤ 3 x ULN unless there is liver involvement by lymphoma in which case AST and ALT < 5 x ULN

  • For patients for whom P-BV-D therapy is planned, creatinine clearance of ≥ 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula

  • If not receiving anticoagulants: International normalized ratio (INR) OR prothrombin (PT) ≤ 1.5 x ULN

    • If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants
  • If not receiving anticoagulants: Activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN

    • If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants
  • Seronegative for hepatitis C virus (HCV), hepatitis B virus (HBV) (surface antigen negative) OR

    • If seropositive for HBV or HCV, nucleic acid quantitation must be performed. Viral load must be undetectable. Patients with occult or prior HBV infection (defined as negative hepatitis B virus surface antigen [HBsAg] and positive hepatitis B core antibody [HBcAb]) may be included if HBV DNA is undetectable, if they are willing to undergo DNA testing on day 1 of every cycle and every three months for at least 12 months after the last cycle of study treatment
  • Women of childbearing potential (WOCBP): negative urine or serum pregnancy test

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • A male participant must agree to use a contraception during the treatment period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period

  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • Not a woman of childbearing potential (WOCBP) OR
    • A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least (X days/weeks [corresponding to time needed to eliminate any study treatment(s)] [pembrolizumab and/or any active comparator/combination] plus 30 days [a menstruation cycle] for study treatments with risk of genotoxicity) after the last dose of study treatment
  • TO PROCEED WITH SALVAGE TREATMENT: ECOG ≤ 2

  • TO PROCEED WITH SALVAGE TREATMENT: Resolution of treatment-related adverse events (AEs) to baseline or grade 1, whichever is higher

  • TO PROCEED WITH SALVAGE TREATMENT: Measurable disease (at least one non-bony FDG-avid lesion ≥ 1.5 cm in long axis)

  • TO PROCEED WITH SALVAGE TREATMENT: Peripheral neuropathy ≤ grade 2

  • TO PROCEED WITH SALVAGE TREATMENT: ANC ≥ 1,000/mm^3

    • NOTE: Growth factors are permitted
  • TO PROCEED WITH SALVAGE TREATMENT: Platelets ≥ 50,000/mm^3

    • NOTE: Platelet transfusions are permitted
  • TO PROCEED WITH SALVAGE TREATMENT: Hemoglobin ≥ 8 g/dL (no transfusion allowed within 3 days prior to screening)

  • TO PROCEED WITH SALVAGE TREATMENT: Total bilirubin ≤ 2 x ULN or direct bilirubin ≤ 2 x ULN for patients with Gilbert's disease

  • TO PROCEED WITH SALVAGE TREATMENT: AST ≤ 3 x ULN, or less then 5 x ULN for patients with liver involvement by lymphoma

  • TO PROCEED WITH SALVAGE TREATMENT: ALT ≤ 3 x ULN, or less then 5 x ULN for patients with liver involvement by lymphoma

  • TO PROCEED WITH SALVAGE TREATMENT: Creatinine clearance of ≥ 30 mL/min per 24-hour urine test or the Cockcroft-Gault formula

Exclusion Criteria:

  • Concomitant investigational therapy

  • Live vaccine within 30 days prior to day 1 of protocol therapy (e.g. measles, mumps, rubella, varicella, yellow fever, rabies, Bacille Calmette Guerin [BCG], oral polio vaccine, and oral typhoid)

  • Grade ≥ 2 peripheral neuropathy

  • Requirement for hemodialysis or peritoneal dialysis. Estimated glomerular filtration rate (EGFR) > 30 for pembrolizumab + BV + dacarbazine

  • Known active central nervous system (CNS) involvement by lymphoma including parenchymal and/or lymphomatous meningitis

  • History of prior ≥ grade 3 hypersensitivity to either brentuximab vedotin or pembrolizumab

  • Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)

  • History of another primary malignancy that has been in remission for fewer than 3 years, with the following exceptions:

    • Non-melanoma skin cancer treated with curative intent
    • In situ cervical cancer
    • If the malignancy is expected to not require any systemic treatment for at least 2 years (this exception should be discussed with the study PI)
  • Condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration. Exceptions are:

    • Inhaled or topical steroids and
    • Adrenal replacement doses > 10 mg daily prednisone equivalents in the absence of active autoimmune disease
    • Up to 7 days of 20 mg daily prednisone equivalent after C1D1 for management of lymphoma-related symptoms
  • History of progressive multifocal leukoencephalopathy (PML)

  • Active pneumonitis or interstitial lung disease

  • Prior solid organ or allogeneic stem cell transplantation

  • History of known or suspected hemophagocytic lymphohistiocytosis (HLH)

  • Active, known or suspected autoimmune disease. The following are exceptions:

    • Vitiligo
    • Psoriasis not requiring systemic treatment
    • Hemolytic anemia associated with the lymphoma
    • Type I diabetes mellitus, if adequately controlled with therapy
    • Thyroid disease, if adequately controlled with therapy
    • Conditions not expected to recur in the absence of an external trigger (such exceptions should be discussed with the study PI)
  • Active history of:

    • Hepatitis B (HBV) or C (HCV) infection. Patients with past HBV infection (defined as negative HBsAg and positive hepatitis B core antibody [HBcAb]) are eligible if HBV DNA is undetectable. Patients who are positive for HCV antibody are eligible if polymerase chain reaction (PCR) is negative for HCV RNA
  • HIV positive

  • History of a cerebral vascular event (stroke or transient ischemic attack), unstable angina, myocardial infarction, or cardiac symptoms consistent with New York Heart Association class III-IV within 6 months prior to day 1 of protocol therapy

  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Treatment (P-G, P-BV-D)

See Detailed Description.

Undergo ECHO

Ostatní jména:
  • Echokardiografie
  • EC

Given IV

Ostatní jména:
  • Adcetris
  • SGN-35
  • cAC10-vcMMAE
  • ADC SGN-35
  • Konjugát anti-CD30 protilátka-lék SGN-35
  • Monoklonální protilátka proti CD30-MMAE SGN-35
  • Monoklonální protilátka anti-CD30-monomethylauristatin E SGN-35
  • SGN35
  • SGN 35

Given IV

Ostatní jména:
  • Keytruda
  • MK-3475
  • Lambrolizumab
  • SCH 900475
  • MK3475
  • SCH-900475
  • BCD-201
  • Pembrolizumab Biosimilar BCD-201
  • Pembrolizumab Biosimilar QL2107
  • QL2107
  • GME 751
  • GME751
  • Pembrolizumab Biosimilar GME751
  • MK 3475
  • SCH900475
  • Biosimilární pembrolizumab RPH-075
  • RPH 075
  • RPH-075
  • RPH075
  • Pembrolizumab Biosimilar SB27
  • SB 27
  • SB-27
  • SB27

Undergo collection of blood samples

Ostatní jména:
  • Sběr biologických vzorků
  • Odebrán biovzorek
  • Sbírka vzorků

Undergo PET/CT

Ostatní jména:
  • Lékařské zobrazování, pozitronová emisní tomografie
  • PET
  • PET skenování
  • Skenování pozitronové emisní tomografie
  • Pozitronová emisní tomografie
  • PT
  • Pozitronová emisní tomografie (postup)

Given IV

Ostatní jména:
  • dFdCyd
  • dFdC
  • Difluordeoxycytidin

Undergo PET/CT

Ostatní jména:
  • ČT
  • KOČKA
  • CAT skenování
  • Počítačová axiální tomografie
  • Počítačová tomografie
  • CT vyšetření
  • tomografie
  • Počítačová axiální tomografie (postup)
  • Počítačová tomografie (CT).
  • Diagnostické skenování CAT
  • Typ služby diagnostického skenování CAT

Given IV

Ostatní jména:
  • 4-(Dimethyltriazeno)imidazol-5-karboxamid
  • 5-(Dimethyltriazeno)imidazol-4-karboxamid
  • Asercit
  • Biokarbazin
  • Dakarbazina
  • Dacarbazina Almirall
  • Dakarbazin - DTIC
  • Dakatické
  • Dakarbazin
  • Deticen
  • Detimedac
  • DIC
  • Dimethyl (triazeno) imidazolkarboxamid
  • Dimethyl triazeno imidazol karboxamid
  • dimethyl-triazeno-imidazolkarboxamid
  • Dimethyl-triazeno-imidazol-karboximid
  • DTIC
  • DTIC-Dome
  • Fauldetický
  • Imidazol karboxamid
  • Imidazol karboxamid dimethyltriazeno
  • WR-139007

Ancillary studies

Ostatní jména:
  • Testování fyzické zdatnosti
  • Testování fyzikálních funkcí

Ancillary studies

Ostatní jména:
  • funkční test plic
  • PFT
  • Testování funkce plic
  • Plicní funkční testy

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Complete metabolic response (CMR) to pembrolizumab and gemcitabine (P-G)
Časové okno: During/after cycles 1-8 of P-G (cycle length = 21 days), before initiation of salvage or maintenance therapy or non-protocol lymphoma therapy

Will be estimated by the proportion of response-evaluable patients achieving a best response of CMR, along with the 95% exact binomial confidence interval.

During/after cycles 1-8 of P-G (cycle length = 21 days), before initiation of salvage or maintenance therapy or non-protocol lymphoma therapy

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
CMR
Časové okno: During/after cycles 1-8 of P-G (cycle length = 21 days) or cycles 1-4 of pembrolizumab maintenance (cycle length = 42 days), before initiation of non-protocol lymphoma therapy

Will be estimated by the proportion of response-evaluable patients achieving a best response of CMR, along with the 95% exact binomial confidence interval.

During/after cycles 1-8 of P-G (cycle length = 21 days) or cycles 1-4 of pembrolizumab maintenance (cycle length = 42 days), before initiation of non-protocol lymphoma therapy
Overall response (OR)
Časové okno: During/after cycles 1-8 of P-G (cycle length = 21 days) or cycles 1-4 of pembrolizumab maintenance (cycle length = 42 days), before initiation of non-protocol lymphoma therapy

Will be estimated by the proportion of response-evaluable patients achieving a best response of CMR or partial metabolic response (PMR), along with the 95% exact binomial confidence interval.

During/after cycles 1-8 of P-G (cycle length = 21 days) or cycles 1-4 of pembrolizumab maintenance (cycle length = 42 days), before initiation of non-protocol lymphoma therapy
Progression-free survival (PFS)
Časové okno: From start of P-G treatment to time of disease relapse/progression or death, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median value will be estimated when available.

From start of P-G treatment to time of disease relapse/progression or death, assessed up to 24 months
Duration of response (DOR)
Časové okno: From first achievement of CMR or PMR during/after cycles 1-8 of P-G (cycle length = 21 days) or cycles 1-4 of pembrolizumab maintenance (cycle length = 42 days) to disease relapse/progression or death, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median value will be estimated when available.

From first achievement of CMR or PMR during/after cycles 1-8 of P-G (cycle length = 21 days) or cycles 1-4 of pembrolizumab maintenance (cycle length = 42 days) to disease relapse/progression or death, assessed up to 24 months
Overall survival (OS)
Časové okno: From start of P-G treatment to time of death, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median value will be estimated when available.

From start of P-G treatment to time of death, assessed up to 24 months
Incidence of adverse events
Časové okno: Up to 24 months

Toxicities will be coded and graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) version (v) 5.0. Observed toxicities of study therapy will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity, and attribution.

Up to 24 months
CMR (for patients who receive salvage therapy)
Časové okno: During/after cycles 1-12 of pembrolizumab, brentuximab vedotin, and dacarbazine (P-BV-D) (cycle length = 21 days), before initiation of non-protocol lymphoma therapy

Will be estimated by the proportion of response-evaluable patients achieving a best response of CMR, along with the 95% exact binomial confidence interval.

During/after cycles 1-12 of pembrolizumab, brentuximab vedotin, and dacarbazine (P-BV-D) (cycle length = 21 days), before initiation of non-protocol lymphoma therapy
OR (for patients who receive salvage therapy)
Časové okno: During/after cycles 1-12 of P-BV-D (cycle length = 21 days), before initiation of non-protocol lymphoma therapy

Will be estimated by the proportion of response-evaluable patients achieving a best response of CMR or PMR, along with the 95% exact binomial confidence interval.

During/after cycles 1-12 of P-BV-D (cycle length = 21 days), before initiation of non-protocol lymphoma therapy
PFS (for patients who receive salvage therapy)
Časové okno: From start of P-BV-D treatment to time of disease relapse/progression or death, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median value will be estimated when available.

From start of P-BV-D treatment to time of disease relapse/progression or death, assessed up to 24 months
DOR (for patients who receive salvage therapy)
Časové okno: From first achievement of CMR or PMR during/after cycles 1-12 of P-BV-D (cycle length = 21 days) to disease relapse/progression or death, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median value will be estimated when available.

From first achievement of CMR or PMR during/after cycles 1-12 of P-BV-D (cycle length = 21 days) to disease relapse/progression or death, assessed up to 24 months
OS (for patients who receive salvage therapy)
Časové okno: From start of P-BV-D treatment to time of death, assessed up to 24 months

Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval will be constructed based on log-log transformation. Median value will be estimated when available.

From start of P-BV-D treatment to time of death, assessed up to 24 months
Incidence of adverse events (for patients who receive salvage therapy)
Časové okno: Up to 24 months

Toxicities will be coded and graded using the NCI CTCAE v 5.0. Observed toxicities of study therapy will be summarized by type (organ affected or laboratory determination such as absolute neutrophil count), severity, and attribution.

Up to 24 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Matthew Mei, City of Hope Medical Center

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

20. října 2029

Dokončení studie (Odhadovaný)

20. října 2029

Termíny zápisu do studia

První předloženo

28. listopadu 2025

První předloženo, které splnilo kritéria kontroly kvality

28. listopadu 2025

První zveřejněno (Aktuální)

10. prosince 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

12. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

9. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit